Novel biologic Ab-IPL-IL-17 shows promise for rheumatoid arthritis and inflammatory bowel disease
Researchers have shown that a novel antibody generated to target an 'essential amino acid sequence' of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies ...
Aug 14, 2023
0
60